Multicenter Clinical Evaluation of Etest Meropenem-Vaborbactam (bioMérieux) for Susceptibility Testing of
gradient diffusion
meropenem-vaborbactam
susceptibility testing
Journal
Journal of clinical microbiology
ISSN: 1098-660X
Titre abrégé: J Clin Microbiol
Pays: United States
ID NLM: 7505564
Informations de publication
Date de publication:
23 12 2019
23 12 2019
Historique:
received:
25
07
2019
accepted:
11
10
2019
pubmed:
18
10
2019
medline:
21
7
2020
entrez:
18
10
2019
Statut:
epublish
Résumé
Meropenem-vaborbactam (MEV) is a novel carbapenem-beta-lactamase inhibitor combination antibiotic approved by the U.S. Food and Drug Administration (FDA) for treatment of complicated urinary tract infections, including pyelonephritis, in adults. In this study, we evaluated the performance of Etest MEV (bioMérieux, Marcy l'Etoile, France) compared to that of broth microdilution for 629
Identifiants
pubmed: 31619532
pii: JCM.01205-19
doi: 10.1128/JCM.01205-19
pmc: PMC6935911
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Boronic Acids
0
Drug Combinations
0
vaborbactam
1C75676F8V
Meropenem
FV9J3JU8B1
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2019 American Society for Microbiology.
Références
JAMA. 2018 Feb 27;319(8):788-799
pubmed: 29486041
Int J Antimicrob Agents. 2018 Aug;52(2):144-150
pubmed: 29510189
Infect Dis Ther. 2018 Dec;7(4):439-455
pubmed: 30270406
Antimicrob Agents Chemother. 2019 Feb 26;63(3):
pubmed: 30617090